MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®)
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]
Detailed price information for Longeveron Inc (LGVN-Q) from The Globe and Mail including charting and trades.
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this
Longeveron Announces 1-for-10 Reverse Stock Split
This is the newest page. Registered accounts read further back.